Estimating the Prevalence and Correlates of Problematic Alcohol Use Among Patients Treated for Illicit Substance Disorder in France, 2012-2022.

IF 3 3区医学 Q2 SUBSTANCE ABUSE

Drug and alcohol review Pub Date : 2025-05-19 DOI:10.1111/dar.14078

Eric Janssen, Mike Vuolo, Sophie Véron, Ivette Flores Laffont

{"title":"Estimating the Prevalence and Correlates of Problematic Alcohol Use Among Patients Treated for Illicit Substance Disorder in France, 2012-2022.","authors":"Eric Janssen, Mike Vuolo, Sophie Véron, Ivette Flores Laffont","doi":"10.1111/dar.14078","DOIUrl":null,"url":null,"abstract":"Introduction: Alcohol use among patients in treatment for illicit substance use disorder (SUD) is often overlooked, at best perceived as a secondary issue, despite growing evidence of exacerbated negative health outcomes among polysubstance users.Method: We analyse a nationwide dataset on patients entering treatment for cannabis, opioid, and stimulant use disorders in France between 2012 and 2022. We conduct multilevel logistic regressions to determine the main predictors of problematic alcohol use (PAU) among patients who entered treatment for cannabis (n = 308,906), opioid (n = 255,879) or stimulant (n = 60,211) use disorders.Results: PAU remains a common behaviour among patients with SUD (overall prevalence: 28.2%, 95% confidence interval [CI] 28.1-28.3), with lower prevalence among patients treated for cannabis (27.3%, 95% CI 27.2-27.5) and opioid disorders (27.2%, 95% CI 27.0-27.4), and higher for patients treated for stimulant disorders (36.8%, 95% CI 36.4-37.2). There is an increase in PAU over time for each of the SUD leading to treatment (23.0% in 2012 vs. 29.5% in 2022; 23.3% vs. 31.4% and 29.7% vs. 38.9% respectively). Males, older people, early onset, current use of tobacco, and psychiatric comorbidities are positively associated with PAU.Discussion and conclusions: The increasing prevalence of problematic alcohol use among patients treated for SUD in France remains a source of concern. Screening for both alcohol and drug use among patients in treatment presents a crucial opportunity to prevent and treat SUDs early, especially among patients treated for stimulants.","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dar.14078","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Alcohol use among patients in treatment for illicit substance use disorder (SUD) is often overlooked, at best perceived as a secondary issue, despite growing evidence of exacerbated negative health outcomes among polysubstance users.

Method: We analyse a nationwide dataset on patients entering treatment for cannabis, opioid, and stimulant use disorders in France between 2012 and 2022. We conduct multilevel logistic regressions to determine the main predictors of problematic alcohol use (PAU) among patients who entered treatment for cannabis (n = 308,906), opioid (n = 255,879) or stimulant (n = 60,211) use disorders.

Results: PAU remains a common behaviour among patients with SUD (overall prevalence: 28.2%, 95% confidence interval [CI] 28.1-28.3), with lower prevalence among patients treated for cannabis (27.3%, 95% CI 27.2-27.5) and opioid disorders (27.2%, 95% CI 27.0-27.4), and higher for patients treated for stimulant disorders (36.8%, 95% CI 36.4-37.2). There is an increase in PAU over time for each of the SUD leading to treatment (23.0% in 2012 vs. 29.5% in 2022; 23.3% vs. 31.4% and 29.7% vs. 38.9% respectively). Males, older people, early onset, current use of tobacco, and psychiatric comorbidities are positively associated with PAU.

Discussion and conclusions: The increasing prevalence of problematic alcohol use among patients treated for SUD in France remains a source of concern. Screening for both alcohol and drug use among patients in treatment presents a crucial opportunity to prevent and treat SUDs early, especially among patients treated for stimulants.

查看原文本刊更多论文

估计2012-2022年法国非法药物治疗患者中酒精使用问题的患病率和相关因素

导读：在治疗非法药物使用障碍（SUD）的患者中，酒精使用往往被忽视，充其量被视为次要问题，尽管越来越多的证据表明多种药物使用者的负面健康后果加剧。方法：我们分析了法国2012年至2022年间因大麻、阿片类药物和兴奋剂使用障碍而进入治疗的患者的全国数据集。我们进行了多水平logistic回归，以确定因大麻（n = 308,906）、阿片类药物（n = 255,879）或兴奋剂（n = 60,211）使用障碍而进入治疗的患者的问题性酒精使用（PAU）的主要预测因素。结果：PAU在SUD患者中仍然是一种常见的行为（总体患病率：28.2%，95%可信区间[CI] 28.1-28.3），在接受大麻治疗的患者中患病率较低（27.3%,95% CI 27.2-27.5）和阿片类疾病（27.2%,95% CI 27.0-27.4），而在接受兴奋剂治疗的患者中患病率较高（36.8%,95% CI 36.4-37.2）。随着时间的推移，每次SUD导致治疗的PAU都有所增加(2012年为23.0%，2022年为29.5%；23.3% vs. 31.4%, 29.7% vs. 38.9%)。男性、老年人、早发、目前使用烟草和精神合并症与PAU呈正相关。讨论和结论：在法国接受SUD治疗的患者中，越来越多的问题性酒精使用仍然是一个值得关注的问题。对正在接受治疗的患者进行酒精和药物使用筛查，是早期预防和治疗sud的重要机会，特别是在接受兴奋剂治疗的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug and alcohol review SUBSTANCE ABUSE-

CiteScore

4.80

自引率

10.50%

发文量

151

期刊介绍： Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.